Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Puccetti

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Infectious Diseases and Therapy|November 28, 2022
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic ExperienceGiusy Tiseo, Chiara Barbieri, Valentina Galfo, et al.
British Journal of Haematology|March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MMAlessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Infectious Diseases and Therapy|November 28, 2022
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic ExperienceGiusy Tiseo, Chiara Barbieri, Valentina Galfo, et al.
British Journal of Haematology|March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MMAlessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Pageof 5